Redx Pharma PLC (AIM:REDX) said preclinical data on one of its cancer assets points to its potential efficacy in combination with traditional chemotherapy.
RXC004 is being developed to tackle Wnt-ligand driven forms of the disease and is being readied for a phase II trial as a single therapy for people with pancreatic and metastatic colorectal and biliary cancers.
The latest update, to be given to the American Association for Cancer Research next Tuesday (April 12), flags its potential to extend survival when used alongside the standard-of-care chemotherapy.
"This preclinical data further underpins our excitement around the therapeutic potential of RXC004, and the role of effective Wnt pathway blockade, in tackling a number of difficult to treat cancers with high unmet need,” said Dr Jane Robertson, Redx’s chief medical officer.